Veeva: Bigger TAM, lower growth?

Verdict: Same story, new slides but Veeva $VEEV remains a healthy business with ~15% growth and enviable ~44% non-GAAP margins. (!) The Vault CRM migration that went better than feared, with 14 of the top 20 drugmakers committed against 9 a year ago.

The new pieces are Falcon agents and the Aspen CRM platform. None comes with a price, revenue or a date, and the 2030 goal they supposedly support needs only ~11% annual growth. Despite no actual product or pricing management arrives at a $10B incremental TAM?

What's more likely to happen is more of a balanced outcome - seat growth will slow but revenue growth can continue with AI agents making the per-seat value much higher since the system will be doing incremental and valuable work.

Seats vs. Agents: Most SaaS companies are dealing with the same imperative which is to shift from "per seat" pricing to at least a combination of seats and usage. These could be tokens or agent actions but the formula remains a work in progress.

Veeva positions Falcon as "agentic labor" that is "doing the work for you" and is "licensed by the agent," not per user (slides 25, 29). Fine idea but more concept than product - of the 12 agents on slide 30, seven are "developing" and five are only "considering." There's no launch timetable, and management admits sales is "learning a new motion" (slide 29). Last year's deck at least gave dated AI rollouts (prior slide 25).

New Info.

• TAM: up from $20B+ to $30B+ in a year (slide 42 vs prior slide 8), with "agents" added to the definition. Every segment grew exactly 50%: Development 45%, Quality 20%, Commercial 35%. That's last year's split once Clinical and Regulatory & Safety are combined. It's a markup, not a bottom-up build. Penetration "fell" from ~16% to ~12% only because the denominator changed.
• CRM: 200+ Vault CRM customers live (from 100+), 5 of the top 20 live (from 2), 14 committed (from 9) (slide 19 vs prior slide 15). The "25+ migrated, ~300 remaining" count is gone, and so is the September 2030 end-of-life date.
• New markets demoted: last year the move beyond life sciences was a $100B+ "big leap" with "first customers soon" (prior slides 28, 30). Now it's Aspen, "focused on early adopters," with a "chance for greatness" (slide 35). There are still no customers a year later, and "New Markets" has dropped out of both the highlights and the capital-allocation priorities.
• Buybacks: "Always Consider Potential for Capital Return" became "Share Repurchase Program" (slide 36). No size is given.
• Study Suite: clinical operations and clinical data software sold "by the study" through CROs, starting spring 2027 (slide 14). This is a real go-to-market change and the most concrete new revenue lever in the deck.

Observations.

• The 2030 build shifted toward Commercial. Last year the plan was R&D ~$4bn and Commercial ~$2bn (prior slide 37). Now it's Development 40%, Quality 20% and Commercial 40% (slide 43), which works out to about $3.6bn and $2.4bn. Implied growth in R&D plus Quality drops from ~17% a year to ~13%, and Commercial rises from ~7% to ~9%. R&D, which includes clinical, was supposed to be the growth engine. Its target got a ~$400m haircut with no explanation.
• No mention of Salesforce, IQVIA, Medidata or Oracle! Six of the top 20 haven't committed to Vault CRM, and Salesforce's Life Sciences Cloud is the obvious place for them to go. Core CRM is already ~85% penetrated (slide 45). The rest of the growth runway is in EDC (~25%), Safety (~20%), RTSM, eCOA and LIMS (near zero), which is exactly where those incumbents are strongest. Falcon also competes with the labor CROs sell, and those are the same CROs Study Suite wants as a sales channel.
• SMB revenue was flat. Within biopharma, Enterprise went from ~15% of revenue to ~20%, and SMB went from ~35% to ~30% (slide 41 vs prior slide 36). In dollars, SMB is ~$1.0bn both years while Enterprise rose ~50%. Either customers were reclassified without a footnote or emerging biotech stalled. That's an awkward fit with the "Golden Age of Life Sciences" theme on slide 6.
• Margin is slipping. Non-GAAP operating margin goes from 45% in FY26 to ~44% in FY27E (slide 50). GAAP margin was 28.7% in FY26, with stock comp at 14.8% of revenue. Stock comp in the Q2 cost and opex lines was up ~13% year on year (slide 61 vs prior slide 51). There's no stock-comp target and no GAAP target.
• Billings disappeared. Last year's guidance slide included normalized billings (prior slide 35). This year's doesn't (slide 39).
• Less detail on consulting. Last year it was $90m of revenue, 400+ people and ~25% growth (prior slide 17). Now it's "Strategic and growing" at ~20% of services (slides 21, 47), roughly $130m.
• Commercial cross-sell is the good news. Products per commercial customer rose from 4.10 to 4.40 in a year, after years stuck near 4.0 (slide 58). R&D and Quality customers grew 7% to 1,250 (slide 57).
• Not quantified: Falcon pricing, revenue or launch dates; how many customers buy Vault AI; Aspen customers or spending; buyback size; how the TAM got from $20bn to $30bn; any AI contribution to the $6bn.

Is the stock more interesting? No. At the 35% floor, $6bn of revenue means ~$2.1bn of non-GAAP operating income; at today's margin it's ~$2.6bn. Beating a target this conservative is already the base case. What would justify a higher multiple is evidence that agents add revenue faster than AI removes seats, and the deck left that blank.

The Math. The run rate today is $3.71bn (slide 49). Reaching $6bn by the end of calendar 2030 takes about 11% a year over ~4.5 years. FY27 guidance implies 15% growth ($3.69bn vs $3.20bn, slide 50). At 15% a year, Veeva crosses $6bn around the end of 2029 and reaches ~$7bn by the end of 2030.

The margin floor is just as loose: 35%+ against ~44% now. On $6bn of revenue, that gap is ~$540m of operating income that management has kept the right to spend.

Subscription revenue needs ~12% a year ($3.07bn to $5.2bn). Services needs only ~5% ($645m to $800m), down from 20%+ growth over the past year. That services slowdown is honest: the CRM migration work ends, and fixed-price "AI-Enabled Services" implementations (slide 21) will cut into Veeva's own services revenue. "On Track" is a low bar. Raising the TAM 50% while leaving the goal unchanged tells you there's no AI revenue in the plan.

Updated Targets

What to watch

• Falcon's first priced agents, and whether Veeva ever reports agent revenue or counts.
• The six uncommitted top-20 CRM accounts. Watch for any of them going public with Salesforce.
• Development Cloud growth against the trimmed 2030 path, especially EDC wins against Medidata.
• Margin against ~44%. Does Falcon and Aspen spending start eating into the cushion above the 35% floor?
• Buyback size and pace once a number appears.

Materials: Veeva Systems investor day materials